Results 201 to 210 of about 24,683,651 (289)

Age‐Associated B Cells Contribute to Inflammation Via Antibody‐Independent Mechanisms in Takayasu Arteritis

Arthritis &Rheumatology, EarlyView.
Objective Although Takayasu arteritis (TAK) is not a prototypical autoantibody‐mediated disease, accumulating evidence suggests that B cells are involved. This study aimed to investigate the pathway of B cell activation and its contributions to TAK pathogenesis. Methods Histologic analysis of paravascular lymph nodes and affected arteries was conducted
Chenglong Fang, Xiaoxi Yang, Xiaochuan Sun, Shangyi Jin, Lihong Du, Jinwei Gao, Jing Li, Zhen Chen, Yuexin Chen, Mengtao Li, Xinping Tian   +10 more
wiley   +1 more source

Investigation of helenalin-induced cell death in Bcl-2 overexpressing Jurkat cells [PDF]

, 2010
Hoffmann, Ruth
core   +1 more source

Functional Characterization of Myelodysplastic Syndrome by Multiparameter Flow Cytometry: The Clinical Synergy Between Ki-67 and Bcl-2 and Their Potential Role in Diagnostics and Personalized Therapy. [PDF]

Cancers (Basel)
Wang SJ, Meel RAJNV, Mestrum SGC, Habets THPM, Hopman AHN, Ramaekers FCS, Henskens YMC, Bekers O, Leers MPG.   +8 more
europepmc   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Overcoming the oral delivery challenges of venetoclax: advancing a clinically improved Bcl-2 inhibitor. [PDF]

Drug Deliv Transl Res
Hegishte Y, Joyce P, Prestidge C, Bremmell K.   +3 more
europepmc   +1 more source

Model‐informed optimal dose selection of golcadomide in combination with R‐CHOP in patients with previously untreated aggressive B‐cell lymphoma

British Journal of Clinical Pharmacology, EarlyView.
Aims Golcadomide is a potential first‐in‐class oral CELMoD™ agent for the treatment of lymphoma. This study aims to develop model‐informed drug development (MIDD) approaches to support optimal dose selection of golcadomide in combination with immunotherapy rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) in alignment with ...
Xirong Zheng, Zhiling Yu, Mark Kaplan, Argyrios Gkasiamis, Akshay Sudhindra, Li Zhu, Manisha Lamba, Fan Wu   +7 more
wiley   +1 more source

DrugBank mining with machine learning reveals novel candidates for BCL-2 inhibition. [PDF]

Sci Rep
Park J, Cho S, Lee H, Choi YR, Choi DH, Jeong MY, Lim YS, Hwang SB, Choi J.   +8 more
europepmc   +1 more source

Towards appropriate guidance for the ethical challenges of environmentally sustainable prescribing

British Journal of Clinical Pharmacology, EarlyView.
The environmental impact of medicines poses a significant threat to planetary and public health, making it essential to integrate environmental sustainability into prescribing practices. While the most effective measures to reduce environmental impact, such as reducing unnecessary prescriptions and medication waste, are consistent with appropriate ...
Joost D. Piët, Steven R. Kraaijeveld, Erik M. Donker, Milan C. Richir, Caroline T. A. Moermond, Amy Booth, SanYuMay Tun, Thijs H. Oude Munnink, Patricia M. L. A. van den Bemt, Lorena Dima, Ben J. A. Janssen, Mathilde Jalving, Tomás Mauro van Emden, Fabrizio de Ponti, Robert Likic, João Costa, Marc Labriffe, Charlotte L. Bekker, Carlotta Lunghi, Elisabetta Poluzzi, Michiel A. van Agtmael, Yolande Voskes, Jelle Tichelaar   +22 more
wiley   +1 more source

Crystal structure of Bcl-2 from lymphocystis disease virus 2 in complex with the BH3 domain of zebrafish BaxA. [PDF]

J Microbiol
Lim D, Park SH, Choi JS, Shin HC, Kim SJ, Ku B.   +5 more
europepmc   +1 more source

What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?

Biotechnology and Bioengineering, EarlyView.
Several host cell types have been used to produce rAAVs to date. Cell line‐specific traits that are beneficial in the context of rAAV manufacturing are reviewed here, with the goal of developing a consensus on the ‘ideal’ characteristics that an rAAV production host should possess (created with Biorender.com).
James Conheady, Nicholas Donohue, Alexandra Bogdanovic, Sharon Davin, Brian Glennon, Niall Barron, C. Mark Smales   +6 more
wiley   +1 more source